Fujirebio Collaborates with Stanford Medicine to Advance Infectious Disease Research
Posted on 06 Jun 2025
Fujirebio (Tokyo, Japan) has entered into a collaboration with Stanford Medicine (Palo Alto, CA, USA) to accelerate the adoption of ultrasensitive immunoassays that incorporate single-molecule counting technology developed by Fujirebio’s wholly-owned subsidiary, Fluxus, Inc. (Sunnyvale, CA, USA).
Fujirebio is constantly developing new IVD testing technologies and unique biomarkers with high clinical value. Fluxus is an industry leader and innovator in optofluidic technologies that develops ultrasensitive detection systems and assay solutions to advance the diagnosis, monitoring, and treatment of diseases. Greater test sensitivity can better inform treatment decisions in the clinic, as well as accelerate studies towards therapeutics and preventive strategies against infectious disease threats worldwide.
“Infectious diseases remain one of the greatest global health challenges of our time,” said Goki Ishikawa, President and CEO of Fujirebio Holdings, Inc. “By working with the Stanford Clinical Virology Laboratory under the direction of Professor Benjamin Pinsky and the Stanford Clinical Microbiology Laboratory under the direction of Professor Niaz Banaei, we are bringing together world-class scientific expertise, cutting-edge technology, and global health insights. This collaboration underscores our shared vision to create a healthier, more resilient world.”
“This collaboration represents a significant step forward in our mission to improve public health globally, by combining Fujirebio’s global IVD expertise and Fluxus’ ultrasensitive detection systems with Stanford’s world-renowned research,” added Dr. Peter Wagner, President and CEO of Fluxus, Inc. “We are thrilled to be working with Stanford University’s prestigious infectious disease experts.”
Related Links:
Fujirebio
Stanford Medicine
Fluxus, Inc.
